NCT03679546 - EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

December 16, 2024

Study Completion Date

June 16, 2025

Conditions

Ulcerative Colitis

Interventions

DRUG

Infliximab

Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.

DRUG

Vedolizumab Injection

Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.

Trial Locations (19)

14033

Centre Hospitalier Universitaire de Caen, Caen

22000

Centre Hospitalier de Saint-Brieuc, Saint-Brieuc

25030

Centre Hospitalier Universitaire de Besançon, Besançon

33600

Centre Hospitalier Universitaire de Bordeaux, Bordeaux

34090

Centre Hospitalier Universitaire de Montpellier, Montpellier

42055

Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne

44093

Centre Hospitalier Universitaire de Nantes, Nantes

54500

Centre Hospitalier Universitaire de Nancy, Nancy

59037

Centre Hospitalier Universitaire de Lille, Lille

63003

Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand

69495

Hospices Civils de Lyon, Lyon

75010

Assistance Publique des Hôpitaux de Paris - Hôpital Saint-Louis, Paris

80054

Centre Hospitalier Universitaire d'Amiens-Picardie, Amiens

92110

Assistance Publique des Hôpitaux de Paris - Hôpital Beaujon, Clichy

94000

Assistance Publique des Hôpitaux de Paris - Hôpital Henri Mondor, Créteil

Unknown

Assistance Publique des Hôpitaux de Marseille, Marseille

Centre Hospitalier Universitaire de Nîmes, Nîmes

Centre Hospitalier Universitaire de Toulouse, Toulouse

06202

Centre Hospitalier Universitaire de Nice, Nice

All Listed Sponsors

lead

Rennes University Hospital

OTHER